What is HC Wainwright's Forecast for KYMR FY2026 Earnings?

Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) - Stock analysts at HC Wainwright upped their FY2026 earnings estimates for Kymera Therapeutics in a research note issued on Thursday, June 26th. HC Wainwright analyst A. Fein now expects that the company will post earnings per share of ($3.24) for the year, up from their prior forecast of ($3.35). HC Wainwright currently has a "Buy" rating and a $60.00 target price on the stock. The consensus estimate for Kymera Therapeutics' current full-year earnings is ($2.79) per share. HC Wainwright also issued estimates for Kymera Therapeutics' FY2027 earnings at ($3.53) EPS, FY2028 earnings at ($3.58) EPS and FY2029 earnings at ($3.23) EPS.

A number of other brokerages have also weighed in on KYMR. Stifel Nicolaus assumed coverage on shares of Kymera Therapeutics in a research note on Tuesday, May 20th. They issued a "buy" rating and a $55.00 price target on the stock. Citigroup started coverage on shares of Kymera Therapeutics in a report on Thursday, March 13th. They set a "buy" rating and a $52.00 price objective on the stock. B. Riley raised shares of Kymera Therapeutics from a "neutral" rating to a "buy" rating and upped their target price for the stock from $38.00 to $60.00 in a research note on Tuesday, June 3rd. Bank of America upgraded Kymera Therapeutics from a "neutral" rating to a "buy" rating and set a $51.00 target price for the company in a report on Monday, June 2nd. Finally, Wall Street Zen upgraded Kymera Therapeutics from a "sell" rating to a "hold" rating in a report on Thursday, May 22nd. Two equities research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $59.11.

Kymera Therapeutics Trading Up 0.6%

Shares of NASDAQ:KYMR traded up $0.28 during trading on Monday, hitting $44.81. 240,361 shares of the company's stock traded hands, compared to its average volume of 630,954. The company has a 50-day moving average price of $38.00 and a 200-day moving average price of $35.89. Kymera Therapeutics has a 52 week low of $19.45 and a 52 week high of $53.27. The company has a market cap of $2.92 billion, a price-to-earnings ratio of -14.45 and a beta of 2.18.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last posted its earnings results on Friday, May 9th. The company reported ($0.82) earnings per share for the quarter, topping the consensus estimate of ($0.92) by $0.10. Kymera Therapeutics had a negative return on equity of 30.11% and a negative net margin of 409.07%. The firm had revenue of $22.10 million for the quarter, compared to analyst estimates of $11.38 million. During the same period in the previous year, the company posted ($0.69) earnings per share. The company's revenue for the quarter was up 114.6% on a year-over-year basis.

Hedge Funds Weigh In On Kymera Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Rhumbline Advisers raised its position in shares of Kymera Therapeutics by 9.0% in the first quarter. Rhumbline Advisers now owns 69,928 shares of the company's stock valued at $1,914,000 after purchasing an additional 5,771 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in shares of Kymera Therapeutics by 121.5% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 896,404 shares of the company's stock worth $24,535,000 after acquiring an additional 491,737 shares during the period. Millennium Management LLC grew its position in shares of Kymera Therapeutics by 340.4% in the first quarter. Millennium Management LLC now owns 510,480 shares of the company's stock valued at $13,972,000 after purchasing an additional 394,562 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in shares of Kymera Therapeutics by 6.3% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 30,793 shares of the company's stock valued at $849,000 after purchasing an additional 1,833 shares during the last quarter. Finally, Eventide Asset Management LLC increased its stake in shares of Kymera Therapeutics by 15.2% during the first quarter. Eventide Asset Management LLC now owns 525,138 shares of the company's stock worth $14,373,000 after purchasing an additional 69,410 shares during the period.

Insider Buying and Selling

In other news, CEO Nello Mainolfi sold 30,000 shares of the company's stock in a transaction dated Tuesday, June 3rd. The shares were sold at an average price of $49.00, for a total value of $1,470,000.00. Following the sale, the chief executive officer directly owned 660,482 shares of the company's stock, valued at approximately $32,363,618. This represents a 4.34% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Elena Ridloff sold 12,000 shares of the company's stock in a transaction that occurred on Tuesday, June 3rd. The shares were sold at an average price of $46.10, for a total value of $553,200.00. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 48,349 shares of company stock worth $2,334,301. Corporate insiders own 16.01% of the company's stock.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.